Natural Alternatives International, Inc. (NAII) introduced CarnoSyn® 4X, a new beta‑alanine formulation that delivers more than four times the bioavailability of standard beta‑alanine while eliminating the tingling sensation that has limited its use in wellness products. The proprietary, patent‑pending ingredient is available as a raw‑material powder, giving formulators flexibility to incorporate it into a wide range of products and potentially opening the wellness and healthy‑aging markets to beta‑alanine.
CarnoSyn® 4X is the next evolution of NAII’s CarnoSyn® portfolio, which includes instant‑release and sustained‑release beta‑alanine products. The launch follows clinical studies published in March 2025 that demonstrated the formulation’s enhanced bioavailability and paresthesia‑free profile. NAII’s portfolio is supported by more than 55 clinical studies, and the company’s beta‑alanine products hold New Dietary Ingredient (NDI) status and Self‑Affirmed GRAS status.
NAII’s recent financial performance provides context for the launch. In fiscal 2025, the company reported net sales of $129.9 million, a 14% increase from the $113.8 million reported in fiscal 2024. However, the company posted a net loss of $13.6 million in fiscal 2025, up from a $7.2 million loss in fiscal 2024, reflecting higher operating expenses and investment in product development. Management indicated that the new CarnoSyn® 4X launch is part of a broader strategy to expand revenue streams in the wellness and healthy‑aging segments, where the company sees significant growth potential.
Kenneth Wolf, President and Chief Operating Officer of NAII, said, “The CarnoSyn® brand name has stood for trusted performance in sports nutrition for more than 20 years, and CarnoSyn® 4X represents the next evolution of that legacy.” He added, “CarnoSyn® 4X gives formulators a way to expand the beta‑alanine audience, reaching consumers who may have avoided it because of the tingling sensation, while reinforcing the CarnoSyn® name as a trusted on‑pack signal of performance.”
The CarnoSyn® 4X formulation is closely related to TriBsyn™, another proprietary beta‑alanine complex developed by NAII. TriBsyn™ demonstrated a 4.5‑fold increase in plasma beta‑alanine compared to conventional beta‑alanine in a March 2025 study, and CarnoSyn® 4X builds on that technology to offer a raw‑material powder that can be incorporated into both instant‑release and sustained‑release products.
NAII operates through two primary segments: Private‑Label Contract Manufacturing and Patent & Trademark Licensing. The launch of CarnoSyn® 4X is expected to strengthen the company’s licensing and raw‑material sales, potentially offsetting the net loss in fiscal 2025 and positioning NAII for future profitability as the wellness and healthy‑aging markets expand.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.